BioSpectral Post Jab Cancer Information

Cannabinoids, Ivermectin, and Fenbendazole in Cancer Treatment: Mechanistic Overlaps and Potential Synergies

Cannabinoids exhibit several overlapping mechanisms with ivermectin (IVM) and fenbendazole (FenBen) in cancer treatment, particularly through microtubule disruption, apoptosis induction, and metabolic modulation. Below is a detailed comparison of these mechanisms and their implications for potential cancer therapy combinations.

1. Microtubule Disruption (Similar to Fenbendazole)

Fenbendazole:

• Binds β-tubulin, disrupting microtubule polymerization.

• Leads to mitotic arrest and apoptosis in cancer cells.

Cannabinoids:

• CBD (cannabidiol) and THC (tetrahydrocannabinol) destabilize microtubules in cancer models:

• CBD disrupts tubulin polymerization, impairing mitotic spindle formation in glioblastoma and breast cancer models.

• THC alters microtubule dynamics, potentially impacting cancer cell division.

Overlapping Effects:

• Cannabinoids may enhance FenBen's microtubule-disrupting effects, making them viable combination agents.

2. p53 Activation & Apoptosis (Similar to Both IVM & FenBen)

Fenbendazole & Ivermectin:

• Upregulate p53, increasing apoptosis through BAX/BAK activation.

Cannabinoids:

• CBD & THC upregulate p53, leading to mitochondrial dysfunction and apoptosis.

• Activate caspase-3 and caspase-9, triggering programmed cell death across various cancer types.

Overlapping Effects:

• Cannabinoids may synergize with FenBen or IVM to enhance apoptosis in cancer cells.

3. Metabolic Disruption & AMPK Activation (Similar to FenBen)

Fenbendazole:

• Blocks glucose metabolism in cancer cells, reversing the Warburg effect.

Cannabinoids:

• CBD inhibits glucose uptake by downregulating GLUT1 transporters.

• Activates AMPK, leading to mTOR inhibition and reduced cancer cell growth.

Overlapping Effects:

• Cannabinoids mimic FenBen’s metabolic disruption, suggesting a role in combination therapy.

4. Anti-Inflammatory & Immune Modulation (Similar to Ivermectin)

Ivermectin:

• Modulates immune responses, shifting T-cell and cytokine activity, reducing cancer immune evasion.

Cannabinoids:

• CBD reduces inflammatory cytokines (IL-6, TNF-α) and impacts NRF2 signaling.

• However, NRF2’s detox pathway only functions when a sufficient net negative charge is present in the cell. If you are pale and think using CBD is a panacea, you're missing a critical decentralized mechanism.

• Enhances immune surveillance via CB2 receptor activation on immune cells.

Overlapping Effects:

• Cannabinoids may amplify IVM’s immune modulation in cancer therapy.

Key Cannabinoids With Cancer-Treatment Potential

1. CBD (Cannabidiol)

• Microtubule disruption

• p53 activation → apoptosis

• AMPK activation → metabolic inhibition

• Anti-inflammatory effects (reduces IL-6, TNF-α), alters NRF2 signaling

2. THC (Tetrahydrocannabinol)

• Microtubule destabilization

• Apoptosis induction via CB1 receptor

• Inhibition of tumor angiogenesis

3. CBG (Cannabigerol)

• Inhibits mitochondrial respiration in cancer cells

• Synergizes with chemotherapy

4. THCV (Tetrahydrocannabivarin)

• Reduces tumor cell proliferation

• Modulates AMPK/mTOR pathway

Potential Synergistic Treatment Approaches

• CBD + Fenbendazole: Microtubule disruption + glucose metabolism inhibition.

• CBD/THC + Ivermectin: Immune modulation + apoptosis enhancement.

• Full-spectrum cannabinoids + Metabolic inhibitors: Targeting aggressive cancers.

These compounds represent a decentralized pharmacy from nature, particularly the Amazon Basin, offering potent alternatives for cancer therapy in the jabbed.

From a biophysics perspective, the common thread linking cannabinoids, ivermectin, and fenbendazole is not just what they bind to, but how they change the energetic state of the cancer cell. All three classes of compounds converge on the mitochondria, collapsing the metabolic privilege that tumor cells enjoy. Cannabinoids have been shown in multiple in vitro and animal models to disrupt mitochondrial membrane potential, increase production of reactive oxygen species in cancer cells, and trigger mitochondrial mediated apoptosis while often sparing non transformed cells.  Fenbendazole and ivermectin likewise interfere with mitochondrial respiration and redox balance, nudging the system away from the Warburg phenotype and back toward oxidative metabolism, where dysfunctional cells are more likely to be recognized and eliminated.

In practical terms, this means these molecules are not “magic bullets” but potential amplifiers of what the body is already trying to do when it has enough charge, light, and time. A patient who corrects circadian rhythm, gets full spectrum sunlight, improves sleep, and restores mineral balance is raising their cellular redox potential and exclusion zone water volume. In that higher energy state, p53 signaling, autophagy, and immune surveillance work more coherently. If cannabinoids or repurposed anthelmintics are introduced into a system that is still chronically light deprived, inflamed, and magnetically incoherent, their signal has to fight through biochemical noise. When they are introduced into a more coherent biophysical field, the same microtubule disruption or AMPK activation can tip a cancer cell over the edge into apoptosis instead of producing more chaos.

There is also a systems level implication for how these agents are used. Many laboratory studies use isolated cell lines in static conditions that do not account for the patient’s light environment, EMF load, or mitochondrial heteroplasmy. Yet we know from red and near infrared photobiomodulation research that simply changing the wavelength and timing of light exposure can alter mitochondrial cytochrome behavior, ROS generation, and gene expression in ways that rival or exceed some drug effects. A decentralized protocol that layers morning sunlight, blue light control at night, grounding, cold exposure, and nutrient dense seasonal food with carefully chosen cannabinoids or repurposed drugs is fundamentally different from taking the same compounds under fluorescent light with a screen in your face at midnight. The molecules are the same, but the informational field they act in is not.

Finally, it is important to acknowledge the limits of the current evidence. Most data on fenbendazole and ivermectin in oncology are preclinical or anecdotal, and fenbendazole in particular is not approved for human use; self experimentation carries real risk. Cannabinoids have stronger human safety data but still limited high quality randomized trials in specific cancers, and dosing, delivery, and tumor context clearly matter.  From a BioSpectral perspective, these compounds are best viewed as potential adjuncts within a much larger environmental and biophysical strategy rather than stand alone cures. When framed that way, they fit into a coherent model of cancer as a disease of failed energy, information flow, and circadian timing, and they can be evaluated more intelligently in future clinical research instead of being dismissed as fringe or embraced as panaceas.

• Cannabidiol regulates apoptosis and autophagy in inflammation and cancer: A review
• Fenbendazole induces pyroptosis in breast cancer cells through HK2/caspase-3/GSDME signaling pathway
• Cannabidiol potentiates p53-driven autophagic cell death in non-small cell lung cancer following DNA damage: a novel synergistic approach beyond canonical pathways

• The influence of biomechanical properties and cannabinoids on tumor invasion

Ivermectin’s Role in Blocking SV40 Promoters via Importin α/β Pathway

Mechanism:

• Importin α/β is crucial for shuttling proteins into the nucleus.

• Many viruses, including SV40, hijack this system to facilitate replication.

• Ivermectin inhibits importin α/β, blocking nuclear entry of SV40 Large T antigen, reducing SV40-driven gene expression and viral replication.
  

Experimental Evidence:

1. Wagstaff et al. (2012) showed Ivermectin inhibits importin α/β-mediated nuclear import in HIV-1 and Dengue viruses. (Source: PMC)

2. SV40 Large T Antigen requires importin α/β for nuclear entry, making it a potential target. (Source: Wikipedia)

Fenbendazole’s Role in Cancer Treatment

1. Microtubule Disruption (Primary Mechanism)

• Binds β-tubulin, disrupting mitotic spindle formation.

• Leads to G2/M cell cycle arrest, triggering apoptosis.
  

2. p53 Activation & Apoptosis Induction

• Inhibits BCL-2, shifting towards pro-apoptotic pathways.

• Induces oxidative stress in cancer cells.
  

3. Glucose Metabolism Disruption (Warburg Effect Reversal)

• Reduces glucose uptake via GLUT1 downregulation.

• Activates AMPK, leading to tumor suppression.
  

4. Synergistic Effects with Radiation & Chemotherapy

• Enhances DNA damage accumulation.

• Weakens microtubule integrity, increasing radiation sensitivity.

Implications for Triple Negative Breast Cancer in the COVID Era

• Stage 4 triple-negative breast cancer is increasing post-jab.

• Psilocybin & cannabinoids have potential in treating SV40-induced cancers.

• Psilocybin activates p53, similar to FenBen and CBD.

• Sunlight regulates the kynurenine pathway, influencing melanin renewal and immune resilience.
  

Conclusion

Cannabinoids share multiple anti-cancer properties with Fenbendazole and Ivermectin, particularly in microtubule inhibition, p53 activation, metabolic disruption, and immune modulation. These findings suggest synergistic potential in cancer treatment, especially for the jabbed population. Decentralized research from the Amazon Basin is crucial in unlocking new therapeutic applications.

References

1. YouTube Source 1

2. YouTube Source 2

3. YouTube Source 3

4. NEJM Study